Biomarker Technologies Market Size was valued at USD 34.39 billion in 2023. The Biomarker Technologies market industry is projected to grow from USD 37.56 Billion in 2024 to USD 69.55 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.01% during the forecast period (2024 - 2032). Increased prevalence of chronic diseases, rising healthcare expenditure, and rising standard of living are the key market drivers enhancing market growth.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Personalized medicine relies heavily on biomarkers for a wide range of purposes such illness diagnosis, prognosis, and tailored treatment. The shortcomings of conventional methods of disease detection and therapy have boosted interest in personalized medicine. Personalized medicine is becoming increasingly popular among patients with cancer and immune system illnesses. The growing interest in customized healthcare is one of the main forces pushing the market for biomarkers forward.
Demand for novel biomarker-based tests is being driven in part by the growing popularity of companion diagnostics for use in individualizing patient care. Companion diagnostics are a growing part of the market since companies are investing more money in their development. Revenue growth in the Biomarker Technologies market is also anticipated to be aided by the great potential of emerging economies.
In addition, biomarkers are used in medication research since they can detect drug-related side effects at an early stage. Biomarkers are also used in customized treatment since they reveal delicate information about the development of a disease. Cancer, viral disorders, autoimmune diseases, and many more may all be diagnosed with the use of biomarkers. This is because they have the unique ability to serve as biomarkers for various disorders.
In February 2024, Abbott Laboratories and Fujirebio initiated a partnership in which they expect to create a neurology biomarker assay for use on Abbott’s Alinity i. This aims to help the research that will detect neurofilament-light chain (Nf-L).
In January 2024, Agilent Technologies Inc. entered into a pact with Incyte, a firm that has expertise in companion diagnostics (CDx) development, so as to provide support for the commercialization and development of the latter's oncology and hematology portfolio.
In January 2024, Merck KGaA announced that it would engage with Quibim, an imaging data conversion company used for actionable predictions about cancer progression and treatment response. The target is employing biomarkers and radiomics to forecast sensitivity and the response of cancer patients undergoing immunotherapy.
The European Consortium project Predictom has been at the forefront of using real-world data (RWD) combined with AI‐based screening to detect those who show early stages of Alzheimer's disease; thus, GE HealthCare in 2023 led this industrial initiative. The Predictom project aims to develop a digital platform that is expected to aggregate participant RWD in different screening stages, including imaging, blood, cerebrospinal fluid, electrophysiological and digital biomarkers.
2022 saw Labcorp introduce one of the first widely available assays that provide direct evidence for neurodegeneration and neuronal injury. Neurofilament Light Chain (NfL) is its name, and it’s a blood-based biomarker test capable of identifying signs consistent with various neurological disorders, thereby establishing more efficient diagnostic paths toward therapeutic options. Elevated NfL levels signal neuronal injury from conditions such as multiple sclerosis, Alzheimer's or Parkinson’s diseases or even brain injury like concussion.
GERO , in 2023, forged a strategic alliance with FOXO Technologies Inc., directed at advancing the discovery of epigenetic aging biomarkers targeted toward human beings. Consequently, due to the diverse benefits and operations undertaken by principal market participants, segment growth is anticipated to accelerate greatly.
In November 2023, QIAGEN released three new kits that can be used on its QIAcuity systems together with a major software upgrade intended to enhance the application portfolio of digital PCR technology across areas such as cell and gene therapies, DNA and RNA quantification, or food and pharmaceutical safety.
Biomarkers are prominently used in companion diagnostics, personalized medicine, disease risk assessment, and drug discovery and development. The rising adoption of biomarkers in disease diagnostics is one of the major factors expected to drive the market CAGR growth during 2019-2026. Biomarkers play a prominent role in personalized medicine, including various applications such as diagnosis, prognosis, and targeted therapies for numerous disease conditions. Personalized medicine has gained acknowledgment due to limitations in traditional disease diagnosis and treatment procedures. Patients with cancer and immunological disorders are inclined toward tailored treatment options based on clinical and genetic features. The rising demand for personalized medicine is one of the major factors driving the demand for biomarkers, fueling the market's growth.
Additionally, the increasing usage of companion diagnostics as a tool for personalized patient treatment is propelling the demand for new biomarker-based tests in the market. For instance, the Trofile assay is used to determine the tropism of the human immunodeficiency virus (HIV) and the likelihood of a patient responding to the treatment by Selzentry. Selzentry (Maravoric) by Pfizer is a chemokine receptor antagonist developed for the treatment of HIV. Furthermore, increasing investment by various key market players in developing companion diagnostics is also an additional factor augmenting the market growth. For instance, in April 2019, QIAGEN N.V. entered into a service agreement with LabCorp to provide cancer patients access to QIAGEN's companion diagnostic products following regulatory approvals of drugs and their associated tests—moreover, advantages offered by a biomarker in drug development and increase in genome mapping programs. However, high initial capital investments required for biomarker discovery and lack of awareness regarding biomarker technologies hamper the growth of the biomarker technologies market. Furthermore, the high potential of emerging economies is expected to provide opportunities for the growth of the Biomarker Technologies market revenue during the forecast period.
Based on Product, the Biomarker Technologies market segmentation includes consumables and instruments. The consumables segment dominated the market because consumables are a crucial part of biomarker testing and are required for performing various technologies. Therefore, this leads to the growth of this market. On the other side, the instruments segment is the fastest growing segment during the forecast period, owing to the technological advancements which have rendered these instruments more precise and quick. Moreover, the rise in the adoption of biomarker technologies across various fields of science contributes to the market growth of biomarker technologies.
Figure 1 Biomarker Technologies Market, by Product, 2022&2032 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Based on Profiling Technology, the Biomarker Technologies market segmentation includes PCR, imaging technology, and NGS. The PCR segment dominated the marketdue to its ability to amplify DNA and RNA samples and detect genetic mutations. PCR technology is widely used in medical and biological research, diagnostic laboratories, and forensic labs.
Based on Application, the Biomarker Technologies market segmentation includes cancer and infectious disease. The cancer segment dominated the market; the segment's growth is due to an increase in demand for rapid & accurate diagnostic tools and a rise in the incidence of cancer biomarker.Hence, using biomarkers to detect cancer, estimate prognosis, monitor response to the treatment, and check for the development of resistance to treatment is crucial in disease management. Furthermore, an increase in the demand for personalized medicines, coupled with growing collaborations between pharmaceutical and diagnostic companies, is anticipated to drive the segment.
The Biomarker Technologies market segmentation, based on research areas, includes genomics and proteomics. The genomics segment dominated the market because it involves the identification, quantification, and analysis of proteins, which play a crucial role in the diagnosis, treatment, and prevention of various diseases. Proteomics technologies, such as mass spectrometry and protein microarrays, are widely used in drug discovery and development, personalized medicine, and clinical diagnostics.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American biomarker technologies market will dominate due to the high disease burden, increased consumer awareness about biomarkers, supportive government initiatives, technological advancements, and healthcare infrastructure improvements that will boost the Region's market growth.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 BIOMARKER TECHNOLOGIES MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe Biomarker Technologies market accounts for the second-largest market share due to the increased prevalence of chronic diseases, rising healthcare expenditure, and rising standard of living. Further, the German Biomarker Technologies market held the largest market share, and the UK Biomarker Technologies market was the fastest-growing market in the European Region.
The Asia-Pacific Biomarker Technologies Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due toa surge in funding for biomarkers discovery, the high prevalence of cancer, rising research initiatives, and the low cost of clinical trials in developing nations are expected to support regional growth. Moreover, China’s Biomarker Technologies market held the largest market share, and the Indian Biomarker Technologies market was the fastest-growing market in the Asia-Pacific region.
Biomarker Technologies Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the biomarker technologies market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The biomarker technologies industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Biomarker Technologies industry to benefit clients and increase the market sector. The Biomarker Technologies industry has offered some of the most significant medical advantages in recent years. Major Biomarker Technologies market players include Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Roche, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Danaher Corporation Siemens Healthcare, and others, are attempting to increase market demand by investing in research and development operations.
QIAGEN N.V., the corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. Furthermore, European, American, and Asian regional headquarters are located in respectively Hilden, Germany, Maryland, United States, and Shanghai, China.QIAGEN N.V. announced the launch of its FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumors; this will help them expand their precision medicine portfolio for Lung Cancer.
Key Companies in the biomarker technologies market include
Biomarker Technologies Industry Developments
May 2021 QIAGEN N.V. announced the launch of its FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumors; this will help them expand their precision medicine portfolio for Lung Cancer.
April 2021 F. Hoffmann-La Roche Ltd announced a series of five new uses for their cardiac biomarkers using the Elecsys technology. These biomarkers have been proven successful in supporting cardiovascular disease management.
September 2020 Thermo Fisher Scientific announced a collaboration with AstraZeneca and the University of Nebraska Medical Center. This collaboration would help the company develop new solutions to address the unmet needs in clinical biomarkers discovery.
August 2023, with the use of epigenetics and AI, FOXO Technologies Inc., a pioneer in the commercialization of epigenetic biomarker technologies, has made strides toward its goal of generating data-driven insights that support optimal health and longevity. This development occurred in August 2023. FOXO has successfully used predictive AI and high-throughput automation to estimate parameters linked with human lifespan using epigenetic biomarkers, thanks to its partnership with DataRobot, the pioneer in Value-Driven AI. There is a strong correlation between health, lifespan, and the presence of epigenetic biomarkers.
In June 2023, by making a strategic investment in Sonde Health, a digital medicine company based in the United States that specializes in the detection of various diseases such as mental health and respiratory disorders through the analysis of voices, the leading South Korean telecom company KT will boost the competitiveness of the artificial intelligence-based health diagnosis business in June 2023. Sonde Health has created a number of vocal biomarker technologies that can detect and track changes in voice strength, pitch, and vocal tract movement in response to underlying medical disorders.
In June 2023, Ozette Technologies, Inc., a technology-driven life sciences business, announced a partnership with Umoja Biopharma, Inc., a revolutionary immuno-oncology company developing commercially available medicines for solid and hematologic malignancies. Umoja plans to conduct its preclinical research using Ozette's AI-driven single-cell technology. Research and development (R&D) assistance and biomarker endpoint evaluation from preclinical tumor-bearing humanized mice models will be performed with the help of the Ozette PlatformTM.
| Report Attribute/Metric | Details |
| Market Size2023 | USD 34.39 billion |
| Market Size 2024 | USD 37.56 billion |
| Market Size2032 | USD 69.55 billion |
| Compound Annual Growth Rate (CAGR) | 8.01%(2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Profiling Technology,Application, Research Area, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Roche, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Danaher Corporation, Siemens Healthcare |
| Key Market Opportunities | Increasing research & development investments by industry players and governmental initiatives supporting research |
| Key Market Dynamics | Increasing prevalence of chronic diseases Rising healthcare expenditure and rise in the standard of living |
Biomarker Technologies Market Highlights:
Frequently Asked Questions (FAQ) :
The Biomarker Technologies market size was valued at USD 34.39 Billion in 2023.
The market is projected to grow at a CAGR of 8.01%during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market areAbbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Roche, Waters Corporation, Danaher Corporation, Shimadzu Corporation, Danaher Corporation, and Siemens Healthcare.
The consumables category dominated the market in 2023.
The cancer had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
